Free cash flow · Fiscal year 2025
| 1 | Johnson & JohnsonJNJ | $19.7B |
|---|---|---|
| 2 | AbbVieABBV | $17.8B |
| 3 | UnitedHealth GroupUNH | $16.1B |
| 4 | Bristol Myers SquibbBMY | $12.8B |
| 5 | MerckMRK | $12.4B |
| 6 | AstraZenecaAZN | $11.8B |
| 7 | Gilead SciencesGILD | $9.5B |
| 8 | PfizerPFE | $9.1B |
| 9 | Novo Nordisk A SNVO | $8.9B |
| 10 | Cigna GroupCI | $8.6B |